- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
SOX9 Antibody / Microarray Specificity Validated Antibody [clone PCRP-SOX9-1A2] (V8969)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
|
V8969-100UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 100 ug | 559 | |
|
|
V8969-20UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 20 ug | 259 | |
|
|
V8969SAF-100UG | 1 mg/ml in 1X PBS; BSA free, sodium azide free | 100 ug | 559 |
| Availability | 1-3 business days |
| Species Reactivity | Human |
| Format | Purified |
| Host | Mouse |
| Clonality | Monoclonal (mouse origin) |
| Isotype | Mouse IgG2b |
| Clone Name | PCRP-SOX9-1A2 |
| Purity | Protein A/G affinity |
| UniProt | P48436 |
| Localization | Nuclear |
| Applications | Immunohistochemistry (FFPE) : 1-2ug/ml |
| Limitations | This SOX9 Antibody / Microarray Specificity Validated Antibody is available for research use only. |
|
Review this product on BioCompare and get a $20 Amazon gift card
|
Related Products
|
SRY-box transcription factor 9 (SOX9) is a nuclear transcription factor that plays a central role in developmental biology, epithelial differentiation, and lineage specification, with well-established relevance in cancer progression and stem-like cell regulation. SOX9 Antibody is widely used to assess nuclear transcriptional activity in tissue sections, and SOX9 Antibody / Microarray Specificity Validated Antibody provides enhanced confidence in immunohistochemistry through independently verified proteome-wide specificity.
In immunohistochemistry of formalin-fixed, paraffin-embedded (FFPE) tissues, precise detection of nuclear proteins requires antibodies with minimal cross-reactivity. SOX9 antibody, also referred to as SRY-box transcription factor 9 antibody, is commonly applied to evaluate epithelial progenitor compartments, ductal structures, and tumor cell populations exhibiting lineage plasticity. Because transcription factors often share conserved domains, non-specific binding can obscure interpretation, particularly in complex tissue microarrays containing diverse cell types.
This antibody has been validated using human protein microarray technology, demonstrating highly selective binding to SOX9 with a dominant signal intensity relative to all other tested proteins. The absence of significant off-target interactions across the proteome supports highly specific antigen recognition. This level of specificity is particularly valuable in tissue microarray (TMA) studies, where hundreds of normal and cancer tissue cores are analyzed in parallel and consistent staining fidelity is essential for accurate comparative interpretation.
In FFPE human tissue microarrays, SOX9 expression is observed as distinct nuclear staining in epithelial progenitor cells, ductal epithelial structures, and selected lineage-restricted cell populations. Normal tissues show compartmentalized nuclear positivity corresponding to known developmental and differentiation-associated expression patterns, while most stromal and fully differentiated tissues exhibit low to absent signal. Across cancer TMAs, SOX9 nuclear staining is frequently detected in tumors with progenitor-like or stem-associated phenotypes, supporting its role in tumor initiation, progression, and cellular plasticity.
The integration of microarray specificity validation with tissue microarray-based immunohistochemistry enables reliable discrimination between true biological signal and potential background staining. Clean nuclear localization, low non-specific signal, and reproducible staining across large TMA panels support the use of this antibody for high-throughput tissue profiling and biomarker evaluation studies.
SOX9 functions downstream of key signaling pathways including Wnt/beta-catenin, Notch, Hedgehog, and TGF-beta, where it regulates transcriptional programs governing differentiation and cell fate decisions. Its expression is widely studied in cancers such as pancreatic, colorectal, lung, and ovarian carcinoma, where it is associated with tumor cell plasticity and progenitor-like states. Accurate immunohistochemical detection of SOX9 is therefore critical for investigating these biological processes in both normal and diseased tissues.
Overall, SOX9 Antibody is well suited for immunohistochemistry applications requiring high specificity, consistent nuclear staining, and reliable performance across FFPE tissue microarrays. Its proteome-wide validated selectivity and robust staining characteristics support confident interpretation of SOX9 expression in large-scale tissue analysis studies.
This SOX9 antibody is part of a broader SOX9 antibody panel offered by NSJ Bioreagents.
Optimal dilution of the SOX9 Antibody / Microarray Specificity Validated Antibody should be determined by the researcher.
Recombinant human full-length SOX9 protein was used as the immunogen for the SOX9 antibody.
Aliquot the SOX9 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
SOX9 antibody, SRY-box transcription factor 9 antibody, SOX9 microarray validated antibody, SOX9 specificity validated antibody, SOX9 immunohistochemistry antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz
